Managing atypical hemolytic uremic syndrome: chapter 2
Related Experiment Video
Updated: Apr 12, 2026

Continuous Manual Exchange Transfusion for Patients with Sickle Cell Disease: An Efficient Method to Avoid Iron Overload
Published on: March 14, 2017
11] Stead Family Department of Pediatrics, University of Iowa, Iowa City, USA [2] Department of Internal Medicine, University of Iowa, Iowa City, USA.
Abstract:
Licht et al. present the 2-year follow-up data of the landmark trials studying the efficacy of eculizumab in the treatment of atypical hemolytic uremic syndrome (aHUS). They report sustained improvements in hematologic parameters, continued safety, and additional improvements in kidney function with extended treatment. This report adds a layer of comfort to our care of patients with this rare disease; however, it is unlikely to be the final chapter in the treatment of aHUS.
More Related Videos
Related Concept Videos
Nephrotic Syndrome III : Nursing Management
Acute Kidney Injury V: Interprofessional Care
Hemodialysis III: Nursing Management
Nephrotic Syndrome II : Assessment and Medical Management
Acute Kidney Injury VI: Nursing Management
Chronic Kidney Disease IV: Nursing Management

